Drug intelligence / Profile preview

Ricrolin

Development stage
Phase 3
Lead developer
Sooft Italia
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Ricrolin is a sterile ophthalmic drug formulation containing riboflavin (vitamin B2) at a concentration of 0.1%, used as eye drops for corneal collagen cross-linking (CXL) procedures in the treatment of keratoconus and secondary corneal ectasias[3][5]. The mechanism involves riboflavin acting as a photosensitizer that, upon activation by ultraviolet A (UVA) light, generates reactive oxygen species leading to the formation of new covalent bonds between collagen fibers in the cornea. This process increases biomechanical stability and halts disease progression[3]. Specialized formulations such as Ricrolin Plus are designed for enhanced penetration using iontophoresis-assisted delivery through an intact epithelium[1][4][6]. The product is intended exclusively for external ocular use.

Brand names
RicrolinRicrolin PlusRicrolin TE
Other names
riboflavin 0.1% ophthalmic solution
02

Targets

Corneal stromal collagen lysine and hydroxylysine residues

Beyond the preview

Go deeper on Ricrolin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ricrolin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call